Certified by Founder
Lodge
Sift Biosciences
start up
United States
- San Carlos, CA
- 19/02/2026
- Pre-Seed
- $3,700,000
Using AI and high-throughput T-cell screening, Sift is developing a new class of T-cell modulators to treat cancers and autoimmune diseases.
- Industry Biotechnology Research
- Website https://siftbio.com/
- LinkedIn https://www.linkedin.com/company/sift-biosciences/
Related People
Yue Clare Lou, Ph.D.Co Founder
United States -
San Francisco Bay Area
Scientist | Founder
Immunology | Cancer <> AI/Bioinformatics <> Microbiology
Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
Mosaic(US) | $18,000,000 | (Apr 23, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)
Bubble Robotics | $5,000,000 | (Apr 23, 2026)